phase i study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of sp-8008

Conditions: Acute Coronary Syndrome; Stroke

Summary: this is a single-centre, double-blind, randomised, placebo-controlled single oral-dose escalation study in healthy male subjects. it is planned to enrol approximately 48 subjects into up to 6 planned dose level cohorts. subjects will be randomly assigned to receive a single oral dose of active investigational medicinal product (imp) or matching placebo in a sequential escalating manner with at least 14 days planned between dose cohorts. dose review of the preceding dose will take place during the 14 day interval. the study will consist of escalating single doses in sequential cohorts. each dose level cohort will consist of 8 subjects; 6 subjects will receive sp-8008 and 2 subjects will receive placebo according to the randomisation schedule. for all dose levels the first 2 sentinel subjects will be randomised 1:1 to placebo or sp-8008, and the remaining 6 subjects will be randomised 1:5 to placebo or sp-8008, respectively.

investigational medicinal product (imp) will be administered at only 1 dose level at a time. following each of periods 1, 2, 3, 4, and 5, there will be a period of interim analysis and review of safety, pk and available pd data from the previous period(s) in order to determine which sp 8008 formulation and dose to administer further regimens. administration at the next dose level will not begin until the safety and tolerability of the preceding dose level have been evaluated and deemed acceptable by the investigator and sponsor, and the exposure of sp-8008 remains within the pre specified limits following interim review. there will be an interval of no less than 14 days between the dosing of successive cohorts, unless a subject cohort returns to a dose that is lower than that already given in a previous cohort eg to obtain dose linearity information. dose escalation will be guided by emerging safety, pk and available pd data and confirmed after each interim data review meeting. there is the option to assess the safety, pk and pd of an alternative formulation. this formulation will be invoked if, following review of data from the preceding periods, it is decided that the exposure from the current formulation may not be ideal for future development.

Eligibility criteria:
inclusion criteria: 1. healthy males 2. age 18 to 55 years of age at the time of signing informed consent 3. body mass index of 18.0 to 32.0 kg/m2 as measured at screening 4. good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), electrocardiogram (ecg) and laboratory investigations (haematology, coagulation, clinical chemistry and urinalysis) and bleeding time (bleeding time may be measured on day 1) 5. must be willing and able to communicate and participate in the whole study 6. must provide written informed consent 7. must agree to adhere to the contraception requirements exclusion criteria: 1. female subjects 2. subjects who had received any investigator medicinal product (imp) in a clinical research study within the 3 months or 90 days prior to day 1 3. subjects who were study site employees, or immediate family members of a study site or sponsor employee 4. subjects who had previously been enrolled in this study 5. history of any drug or alcohol abuse in the past 2 years 6. regular alcohol consumption \>21 units per week (1 unit = ½ pint beer, or a 25 ml shot of 40% spirit, 1.5 to 2 units = 125 ml glass of wine, depending on type) 7. current smokers and those who had smoked within the last 12 months. a confirmed breath carbon monoxide (co) reading of greater than 10 ppm at screening or admission current users of e-cigarettes and nicotine replacement products and those who had used these products within the last 12 months 8. current users of e-cigarettes and nicotine replacement products and those who had used these products within the last 12 months 9. subjects without suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening 10. clinically significant abnormal biochemistry, haematology, coagulation or urinalysis as judged by the investigator including investigator medicinal product (pt) \>14 s, investigator medicinal product (aptt) \> reference laboratory values, platelet count ≤100,000 mm3, alanine aminotransferase (alt)/ aspartate aminotransferase (ast) \>2× upper limit of normal, white blood cells ≤3000 × 109/l, haemoglobin \ 20 µmol/l, bleeding time \>15 min 11. any clinically significant medical disorders increasing the tendency to bleed easily, or a history of recent trauma or surgery, or a history of gout and renal stones 12. confirmed positive drugs of abuse test result 13. positive hepatitis b surface antigen (hbsag), hepatitis c virus antibody (hcv ab) or human immunodeficiency virus (hiv) results 14. evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (crcl) of \<80 ml/min using the cockcroft-gault equation 15. history of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator 16. serious adverse reaction (sae) or serious hypersensitivity to any drug or the formulation excipients 17. presence or history of clinically significant allergy requiring treatment, as judged by the investigator. hay fever was allowed unless it was active 18. donation or loss of greater than 400 ml of blood within the previous 3 months 19. subjects who were taking, or had taken, any prescribed or over-the-counter drug, herbal remedies or supplements in the 14 days before imp administration; these included fish oil/omega-3, st. john's wort, ginseng, garlic, gingko, saw palmetto, echinacea, yohimbine, liquorice and black cohosh. exceptions may have applied on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the principal investigator (pi) and sponsor's medical monitor. 20. failure to satisfy the investigator of fitness to participate for any other reason

Keywords: antiplatelet drug shear stress sp-8008